To determine the safety, toxicity, and maximum-tolerated dose of a sequence-specific combination of the histone deacetylase inhibitor (HDACi), valproic acid (VPA), and epirubicin in solid tumor malignancies and to define the clinical feasibility of VPA as an HDACi.
PATIENTS AND METHODS
Patients were treated with increasing doses of VPA (days 1… (More)
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.